Preparation of Human Tissues Embedded in Optimal Cutting Temperature Compound for Mass Spectrometry Analysis
April 27th, 2021
Sphingolipids are bioactive metabolites with well-established roles in human disease. Characterizing alterations in tissues with mass-spectrometry can reveal roles in disease etiology or identify therapeutic targets. However, the OCT-compound used for cryopreservation in biorepositories interferes with mass-spectrometry. We outline methods to analyze sphingolipids in human tissues embedded in OCT with LC-ESI-MS/MS.
Overview
This article presents a detailed protocol for the removal of optimal cutting temperature (OCT) compound from cryopreserved human tissue specimens, enabling accurate quantification of sphingolipids using liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). The workflow allows researchers to utilize biorepository samples, expanding the scope of lipidomics studies in human disease research.
Key Study Components
Area of Science
- Lipidomics
- Mass spectrometry
- Human tissue analysis
Background
- Sphingolipids are important cellular components involved in metabolism and disease.
- Mass spectrometry is a key tool for analyzing sphingolipid alterations in disease contexts.
- Retrospective studies using biorepository specimens offer logistical advantages over prospective tissue collection.
- OCT, commonly used for cryopreservation, is incompatible with mass spectrometry and must be removed prior to analysis.
Purpose of Study
- To provide a reproducible protocol for removing OCT from cryopreserved human tissues.
- To enable accurate extraction and quantification of sphingolipids from biorepository samples.
- To demonstrate that sphingolipid content remains stable in OCT-embedded tissues for extended periods.
Methods Used
- Preparation of tissue drying wicks and cleaning of surgical tools with methanol.
- Sequential washing of tissue samples with ice-cold ultrapure water and PBS to remove OCT.
- Weighing of washed tissues for data normalization.
- Lipid extraction using methanol, chloroform, and internal standards, followed by homogenization and sonication.
- Evaporation of solvents, resuspension of lipid extracts, and removal of debris by centrifugation.
- Analysis of sphingolipids by LC-ESI-MS/MS.
Main Results
- The protocol effectively removes OCT without altering sphingolipid content.
- Sphingolipids in OCT-embedded tissues are stable for up to 16 years.
- LC-ESI-MS/MS analysis reveals significant elevation of ceramides and monohexosyl-ceramides in lung adenocarcinoma tumors compared to adjacent normal tissues.
- Retention times of sphingolipid species are influenced by chain length and degree of unsaturation.
Conclusions
- This protocol enables the use of cryopreserved biorepository tissues for sphingolipid analysis by mass spectrometry.
- It broadens the range of available samples for retrospective lipidomics studies.
- The method ensures reliable quantification of sphingolipids in human disease research.
Frequently Asked Questions
Executive Industry Relevance
Enabling mass spectrometry analysis of sphingolipids from OCT-embedded human tissues unlocks retrospective access to large, well-annotated biorepository samples, overcoming a major barrier in translational lipidomics. This workflow expands the discovery pipeline by supporting robust, quantitative lipid profiling in disease-relevant human specimens, increasing predictive confidence for target validation and biomarker research. The protocol's compatibility with long-term archived tissues enhances portfolio flexibility and risk-adjusted decision-making in early discovery and translational studies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of sphingolipid pathway alterations in human disease tissues.
- Supports functional target validation by quantifying lipid species in clinically annotated samples.
- Facilitates mechanistic de-risking by leveraging retrospective cohorts with rich clinicopathological data.
Screening & Assay Development
- Prepares high-quality, reproducible tissue extracts for downstream LC-ESI-MS/MS workflows.
- Standardizes sample normalization and internal standardization for quantitative lipidomics assays.
- Enables scalable screening of archived specimens for biomarker or target discovery.
Translational & Preclinical Research
- Aligns lipidomic outputs with disease phenotypes and clinical variables from biorepository metadata.
- Supports continuity from discovery through preclinical validation using human-relevant samples.
- Reduces translational risk by enabling direct comparison of tumor and matched normal tissues.
Pipeline & Workflow Integration
This protocol bridges early discovery and translational research by enabling robust lipidomic analysis of archived human tissues, supporting workflows from hypothesis testing to biomarker validation.
- Discovery Biology: Facilitates hypothesis-driven interrogation of sphingolipid metabolism in disease contexts.
- Screening: Provides reproducible, quantitative outputs for comparative lipidomics across large sample sets.
- Analytics: Delivers normalized, statistically analyzable data for cross-condition comparisons and cohort studies.
- Translational Research: Integrates with clinical annotation for biomarker alignment and disease mechanism studies.
- Enterprise Reuse: Establishes a reusable workflow for leveraging biorepository assets across multiple programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in lipid target validation and mechanistic studies.
- Operational Value: Standardizes sample preparation and data normalization for reproducibility and scalability.
- Strategic Value: Enables risk-adjusted advancement and capital-efficient use of archived clinical samples.
- Portfolio Impact: Expands accessible sample pools for prioritization and cross-program analyses.
Implementation Considerations
- Requires expertise in tissue handling, lipid extraction, and mass spectrometry analytics.
- Demands access to LC-ESI-MS/MS instrumentation and validated internal standards.
- Necessitates rigorous cross-team standardization for sample processing and data normalization.
- Adaptable to various tissue types but may require validation for non-sphingolipid classes.
- Dependent on quality and annotation of biorepository specimens for maximal translational value.
Biopharma FAQs
Chapters in this video
0:04
Introduction
0:54
Preparation of Tissue-Drying Wicks
1:39
Tissue Washing for Sphingolipidomic Optimal Cutting Temperature-Compound (OCT) Removal
2:41
Tissue Weighing for Data Normalization
4:12
Lipid Extraction
7:03
Results: Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry (LC ESI MS/MS) Analysis of Tissues Following OCT Removal
8:36
Conclusion
